ArticleHormones (Athens, Greece)2026
Baseline TSH within reference range and incident thyroid dysfunction in cancer patients: a retrospective cohort study.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeWhether baseline thyrotropin (TSH) within the reference range predicts thyroid dysfunction in cancer patients remains unclear. We evaluated this association in hospitalized cancer patients with normal baseline thyroid function.
methodsThis retrospective cohort study (October 2020-September 2025) included 532 cancer patients with normal baseline thyroid function and ≥ 1 follow-up test. Baseline TSH was modeled using restricted cubic splines and categorized as low (< 1.02 mIU/L), optimal (1.02-2.00 mIU/L), or high (> 2.00 mIU/L). Primary outcome was overall thyroid dysfunction; secondary outcomes included clinical dysfunction and mortality. Multivariable Cox models and 365-day restricted mean survival time (RMST) analyses were performed.
resultsOverall dysfunction occurred in 175 patients (32.9%). Baseline TSH showed a U-shaped association with overall thyroid dysfunction (P for nonlinearity < 0.001), with the lowest risk at 1.02-2.00 mIU/L. Compared with optimal TSH, low TSH (HR 1.90, 95% CI 1.19-3.03) and high TSH (HR 2.22, 95% CI 1.55-3.18) independently predicted increased risk. RMST analysis confirmed 52.5 and 64.6 fewer dysfunction-free days for low and high groups, respectively (both P < 0.001). High TSH predicted clinical dysfunction (HR 1.71, 95% CI 1.03-2.81); low TSH did not. No association was found with mortality.
conclusionIn hospitalized cancer patients, baseline TSH within the reference range showed a U-shaped association with incident thyroid dysfunction, with lowest risk at 1.02-2.00 mIU/L. Risk stratification within the conventional reference range may inform personalized monitoring strategies during anticancer treatment.
Indexed as
Identifiers
42509470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.